Overview

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

Status:
Recruiting
Trial end date:
2027-01-15
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Collaborator:
Incyte Corporation